Proliferation, differentiation, and survival of erythroid progenitors are ultimately controlled through activation and repression of specific genetic programs. In this perspective article, Drs. Brandt and Koury examine the role of LIM domain-only protein 2 (LMO2) as an important transcriptional regulator in erythropoiesis. See related article on page 479.
Bortezomib is a synthetic small molecule inhibitor of the chymotryptic activity of the 26S proteasome. Effects of bortezomib on normal immune cells have also been previously reported. This study adds to observations on the effects of bortezomib on natural killer (NK) cells. Effects include induction of apoptosis in resting NK cells, together with suppression of NK-mediated cytotoxicity via the
NKp46 pathway. The concern is raised that treatment with bortezomib could interfere with NK cell-mediated attack on tumor cells, or on infected cells. 
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